Interleukin Genetics to Present at the 12th Annual BIO CEO Conference

WALTHAM, Mass., Feb. 4  /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Amex: ILI) announced today that it will make a corporate presentation at the 2010 BIO CEO & Investor Conference. The 12th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf-Astoria in New York.

Interleukin Genetics Chief Executive Officer, Lewis H. Bender, will provide an overview of the Company and discuss recent milestones at 1:00 p.m. ET in Park South of the Waldorf-Astoria.

About Interleukin Genetics

Interleukin Genetics, Inc. (NYSE Amex: ILI) develops and markets genetic tests that empower consumers to prevent certain chronic diseases and that assist pharmaceutical companies in the development and marketing of targeted therapeutics. The Company leverages its research, intellectual property and biomarker development experience to facilitate the emerging personalized health market. Interleukin Genetics markets a line of genetic tests under the Inherent Health brand including Bone Health, Weight Management, Heart Health and Nutritional Needs.  The Company is headquartered in Waltham, MA.  For more information please visit http://www.ilgenetics.com/. 

DATASOURCE: Interleukin Genetics, Inc.



CONTACT:  Media: Erin Walsh, Interleukin Genetics, [phone],





Web Site:  http://www.ilgenetics.com/ 

Copyright